Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 26, 2017 16:15 ET | Source: Bioblast Pharma

Bioblast Pharma Reports First Quarter 2017 Financial Results

TEL AVIV, Israel, May 26, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the first...
April 17, 2017 16:47 ET | Source: Bioblast Pharma

Bioblast Pharma Announces Plans in Response to Nasdaq Notifications Regarding Stockholders’ Equity and Minimum Bid Requirements

TEL AVIV, Israel, April 17, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today that in response to a written...
April 06, 2017 16:55 ET | Source: Bioblast Pharma

Bioblast Announces Termination of Securities Offering

TEL AVIV, Israel, April 06, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today the cancellation of its...
April 06, 2017 16:01 ET | Source: Bioblast Pharma

Bioblast Pharma Announces Termination of Securities Offering

TEL AVIV, Israel, April 06, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today the cancellation of its...
March 10, 2017 16:05 ET | Source: Bioblast Pharma

Bioblast Pharma Announces Receipt of Nasdaq Notification Regarding Stockholders’ Equity

TEL AVIV, Israel, March 10, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today that it received a written...
February 24, 2017 08:00 ET | Source: Bioblast Pharma

Bioblast Pharma Reports Fourth Quarter and Year End 2016 Financial Results

TEL AVIV, Israel, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the...
February 01, 2017 16:01 ET | Source: Bioblast Pharma

Bioblast Pharma Provides Clinical and Development Updates on Trehalose as a Potential Therapeutic for OPMD and Other Neurodegenerative Diseases

TEL AVIV, Israel, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (NasdaqGM:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced new clinical and development...
January 26, 2017 08:00 ET | Source: Bioblast Pharma

Bioblast Pharma to Host Key Opinion Leader Lunch Focused on Orphan Neurological Diseases on February 2

TEL AVIV, Israel, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, will host a KOL lunch on the subject of...
January 18, 2017 08:00 ET | Source: Bioblast Pharma

Bioblast Announces Phase 2a Results of Trehalose in Patients with Spinocerebellar Ataxia Type 3 (SCA3)

Patients Treated with Trehalose Remained Stable According to a Well-Established Clinical Evaluation Scale A Recent Natural History Study in The Lancet Neurology in Patients with SCA3 Noted a Steady...
November 29, 2016 08:00 ET | Source: Bioblast Pharma

Bioblast Pharma Reports Third Quarter 2016 Financial Results

TEL AVIV, Israel, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced financial results for the...